Subject(s)
COVID-19 , Mental Health , Social Support , COVID-19/prevention & control , COVID-19/psychology , Child , Humans , Pandemics , Parents , Physical Distancing , SARS-CoV-2 , School Teachers , Wit and Humor as TopicABSTRACT
Erythroid leukemia is an uncommon form of acute myeloid leukemia (AML) which has previously been associated with a poor prognosis. We present the outcome of 27 patients with AML-M6 (19 de novo and 8 secondary) treated with intensive regimens including bone marrow transplantation (BMT). In the de novo group, median age was 30 years (2-72); 5 cases were under 15 years. Remission rate after induction chemotherapy was 95%. Consolidation in those achieving remission with BMT was 82%. Transplant related mortality was 36%. Median survival for de novo M6 was 2.9 years which was not significantly different to matched controls with AML (non M6). Overall relapse rate was 35%. In contrast, patients with secondary disease had a poor prognosis with lower remission rates (57%) and higher relapse rates (75% of those achieving remission after induction chemotherapy). In our series, the prognosis of patients with AML-M6 was most closely related to age and disease status at presentation (de novo or secondary). The disease is sensitive to AML induction regimens and long-term survival can be achieved with BMT in first complete remission.
Subject(s)
Bone Marrow Transplantation , Leukemia, Erythroblastic, Acute/therapy , Adolescent , Adult , Aged , Child , Child, Preschool , Demography , Humans , Immunophenotyping , Karyotyping , Laboratories , Leukemia, Erythroblastic, Acute/mortality , Middle Aged , Remission Induction/methods , Survival Rate , Treatment OutcomeSubject(s)
Aerospace Medicine , Thrombophlebitis/etiology , Travel , Adult , Female , Humans , Male , Middle Aged , Risk FactorsABSTRACT
Secondary leukaemia has rarely been reported as a complication of autologous stem cell transplantation for AML. We report two cases of AML who presented with well-characterised cytogenetic abnormalities at presentation: t(8;21) and t(15;17) respectively, and who, after achieving complete morphological and cytogenetic remissions post-autograft, developed MDS/AML associated with monosomy 7. This secondary change is most frequently seen following alkylating agent therapy for solid tumours. The secondary leukaemia seen in our patients may thus be due to exposure of the residual stem cells to the alkylating agents used in the transplant conditioning.
